The US Food and Drug Administration (FDA) has approved<unk>  inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. A brief review of<unk>  found no conclusive evidence that it was particularly effective in patients with schizophrenia. A subsequent systematic review considered that the limited evidence did not indicate a clear difference in its effects from other antipsychotics. Available forms<unk>  can be taken by mouth as a capsule or a liquid oral concentrate. It is also available as an intramuscular injection and as a powder for inhalation.
Loxapine
Amoxapine
Aripiprazole
Sertraline
Asenapine
Mirtazapine
Perlapine
Trimipramine